Magenta Therapeutics – LifeCareNews

LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase

CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial…

Magenta Therapeutics Presents Positive MGTA-117 Clinical

– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with…